Amneal Pharmaceuticals, INC 10-Q quarterly reports

Amneal Pharmaceuticals, Inc. announced a significant increase in net revenue and operating income for the second quarter of 2026, driven by growth across its key segments.

Amneal Pharmaceuticals reports a significant increase in net income and gross profit for Q1 2026, driven by robust performance in its Specialty segment and improved manufacturing efficiencies.

Amneal Pharmaceuticals, Inc. reported a return to net income in Q3 2025, driven by revenue growth across all segments and strategic debt refinancing, despite an impairment charge and increased operating expenses.

Amneal Pharmaceuticals Inc. reported significant net income and EPS growth in Q2 2025, driven by new product launches and strategic segment performance, alongside major debt refinancing.

Amneal Pharmaceuticals' Q1 2025 revenue increased by 5.5% year-over-year, driven by growth in Affordable Medicines, AvKARE, and Specialty segments.

Amneal Pharmaceuticals saw a 13.3% increase in revenue year-over-year in Q3 2024, driven by growth in generics, specialty, and AvKARE segments.

Amneal Pharmaceuticals saw a 17.1% increase in revenue in Q2 2024, driven by growth in its Generics and AvKARE segments, while also navigating legal settlements and increased interest expenses.

Amneal Pharmaceuticals experienced a net loss in Q1 2024, impacted by a significant charge related to an opioid litigation settlement, despite a notable increase in revenue.